Science

Neurodegenerative diseases are a heterogeneous group of disorders characterized by progressive degeneration of the structure and function of the central nervous system or peripheral nervous system. AAV based gene therapy is rapidly emerging as a powerful therapeutic strategy for a wide range of neurodegenerative disorders, including Alzheimer's disease (AD) and Parkinson's disease (PD). AAV gene therapy has the potential to provide therapeutic benefit neurodegenerative disorders through several means, including by silencing a mutant allele using RNA interference (RNAi), by introducing a disease-modifying gene, or by using gene-editing technology. Leveraging recent breakthroughs in human genetics and the transformative success of AAV-based clinical trials, our goal is to use a precision medicine approach to slow or stop the progression of neurodegenerative diseases, such as AD and PD.

Adeno-associated viruses (AAVs) have been successfully used to treat a number of rare genetic diseases such as hemophilia, Leber's congenital amaurosis and spinal muscular atrophy. At QLD, we combine AAV and advanced molecular and cellular technologies to provide safe and effective treatment for more common diseases such as neurodegenerative diseases and cancers.

We dedicate ourselves to novel immune cell therapies that are more effective and safer to help cure patients with tumors and immunological diseases. Meanwhile, the Universal Platform we are adopting will significantly reduce manufacturing costs to make our products more accessible to patients.